ES2962812T3 - Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos - Google Patents
Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos Download PDFInfo
- Publication number
- ES2962812T3 ES2962812T3 ES19878837T ES19878837T ES2962812T3 ES 2962812 T3 ES2962812 T3 ES 2962812T3 ES 19878837 T ES19878837 T ES 19878837T ES 19878837 T ES19878837 T ES 19878837T ES 2962812 T3 ES2962812 T3 ES 2962812T3
- Authority
- ES
- Spain
- Prior art keywords
- aoah
- msc
- polypeptide
- promoter
- mscs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01077—Acyloxyacyl hydrolase (3.1.1.77)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752000P | 2018-10-29 | 2018-10-29 | |
| PCT/CA2019/051526 WO2020087160A1 (en) | 2018-10-29 | 2019-10-29 | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2962812T3 true ES2962812T3 (es) | 2024-03-21 |
Family
ID=70462996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19878837T Active ES2962812T3 (es) | 2018-10-29 | 2019-10-29 | Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220010281A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3874029B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7372982B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210086662A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166729A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019370629A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962812T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282820A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202103509RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020087160A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302060A (en) * | 2020-10-16 | 2023-06-01 | Ottawa Hospital Res Inst | Cell-based therapy for viral diseases |
| CN116570711A (zh) * | 2022-12-21 | 2023-08-11 | 上海交通大学医学院附属第九人民医院 | 酰基羧酸水解酶在制备治疗肾脏纤维化疾病的药物中的应用 |
| WO2026101889A2 (en) * | 2024-11-06 | 2026-05-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Acyloxyacyl hydrolase and methods of use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929604A (en) * | 1986-05-28 | 1990-05-29 | Board Of Regents, The University Of Texas System | Lipopolysaccharides of reduced toxicity and the production thereof |
| US5281520A (en) * | 1990-09-12 | 1994-01-25 | Zymogenetics, Inc. | Method for producing acyloxyacyl hydrolase |
| CN101378764A (zh) * | 2005-12-09 | 2009-03-04 | 贝勒研究院 | 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测 |
| JP2011528566A (ja) * | 2008-07-21 | 2011-11-24 | コンプジェン リミティッド | アンジオポエチン由来ペプチド |
| GB0814249D0 (en) * | 2008-08-04 | 2008-09-10 | Cellerix Sa | Uses of mesenchymal stem cells |
| JP2012529895A (ja) * | 2009-06-19 | 2012-11-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗egfr抗体の癌療法における有効性を決定するためのバイオマーカーおよび方法 |
| EP2626369A1 (en) * | 2011-11-24 | 2013-08-14 | Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Engineered mesenchymal stem cells and their therapeutic use |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| RU2658490C2 (ru) * | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| CA2928852A1 (en) * | 2013-11-01 | 2015-05-07 | Regeneron Pharmaceuticals, Inc. | Angiopoietin-based interventions for treating cerebral malaria |
| WO2015090229A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| KR102213527B1 (ko) * | 2014-06-30 | 2021-02-09 | 타이제닉스, 에스.에이.유. | 패혈증 치료용 중간엽 기질세포 |
| PL3242933T3 (pl) * | 2015-01-08 | 2019-08-30 | Apceth Gmbh & Co. Kg | Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat) |
| CA3172801A1 (en) * | 2015-06-12 | 2016-12-15 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| CN108430480B (zh) * | 2015-09-15 | 2022-08-02 | 康干细胞生物科技有限公司 | 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物 |
-
2019
- 2019-10-29 EP EP19878837.4A patent/EP3874029B1/en active Active
- 2019-10-29 JP JP2021547607A patent/JP7372982B2/ja active Active
- 2019-10-29 KR KR1020217015632A patent/KR20210086662A/ko not_active Ceased
- 2019-10-29 AU AU2019370629A patent/AU2019370629A1/en not_active Abandoned
- 2019-10-29 CN CN201980071846.5A patent/CN113166729A/zh active Pending
- 2019-10-29 WO PCT/CA2019/051526 patent/WO2020087160A1/en not_active Ceased
- 2019-10-29 US US17/289,311 patent/US20220010281A1/en not_active Abandoned
- 2019-10-29 ES ES19878837T patent/ES2962812T3/es active Active
- 2019-10-29 SG SG11202103509RA patent/SG11202103509RA/en unknown
-
2021
- 2021-04-29 IL IL282820A patent/IL282820A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019370629A1 (en) | 2021-05-20 |
| WO2020087160A1 (en) | 2020-05-07 |
| EP3874029A1 (en) | 2021-09-08 |
| EP3874029B1 (en) | 2023-08-30 |
| KR20210086662A (ko) | 2021-07-08 |
| CN113166729A (zh) | 2021-07-23 |
| US20220010281A1 (en) | 2022-01-13 |
| IL282820A (en) | 2021-06-30 |
| EP3874029A4 (en) | 2022-08-03 |
| JP2022513379A (ja) | 2022-02-07 |
| JP7372982B2 (ja) | 2023-11-01 |
| CA3116196A1 (en) | 2020-05-07 |
| SG11202103509RA (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101992807B1 (ko) | 조직 재생을 유도하기 위한 펩티드 및 그의 이용 | |
| ES2629086T3 (es) | Sustancia farmacéutica para promover la regeneración funcional de tejido dañado | |
| Mei et al. | Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1 | |
| ES2739129T3 (es) | IL-22 para uso en el tratamiento de la enfermedad gastrointestinal del injerto contra el huesped | |
| CN102711777B (zh) | 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂 | |
| US20110097309A1 (en) | Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue | |
| ES3032739T3 (en) | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression | |
| ES2927406T3 (es) | Potenciación de las propiedades inmunomoduladoras de las MSC mediante treprostinil | |
| ES2727820T3 (es) | Células madre mesenquimatosas modificadas genéticamente que expresan alfa-1 antitripsina (AAT) | |
| US20190117702A1 (en) | Use of asc and asc-cm to treat ards, sars, and mers | |
| ES2581278T3 (es) | Composiciones y métodos para la inmunomodulación | |
| EP3874029B1 (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| JP5706821B2 (ja) | ペリオスチンに誘導される膵臓再生 | |
| JP7672636B2 (ja) | 間葉系幹細胞の動員活性を有するペプチド | |
| Naso et al. | Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa | |
| JP2024522256A (ja) | 免疫寛容を誘導するための合成タンパク質 | |
| CA3116196C (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| HK40057211A (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| HK40057211B (en) | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof | |
| US20230414668A1 (en) | Cell-based therapy for viral diseases | |
| Venkatakrishnan | Cell and Gene Therapy for Treating Acquired and Inherited Corneal Disorders | |
| Khalili | A novel cell therapy for xerostomia in Non-Obese Diabetic mice | |
| Provost | The role of interferon gamma in the regulation of the epithelial responses in allergic airway inflammation | |
| Thawer | The role of pulmonary innate and adaptive immune responses to helminth infection |